These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27589047)

  • 1. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial.
    Demissei BG; Postmus D; Liu LCY; Cleland JG; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Davison BA; Edwards C; Givertz MM; Bloomfield DM; Dittrich HC; Voors AA; Hillege HL
    Int J Cardiol; 2016 Nov; 223():967-975. PubMed ID: 27589047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
    Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
    Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
    N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.
    Metra M; O'Connor CM; Davison BA; Cleland JG; Ponikowski P; Teerlink JR; Voors AA; Givertz MM; Mansoor GA; Bloomfield DM; Jia G; DeLucca P; Massie B; Dittrich H; Cotter G
    Eur Heart J; 2011 Jun; 32(12):1519-34. PubMed ID: 21388992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
    Teerlink JR; Iragui VJ; Mohr JP; Carson PE; Hauptman PJ; Lovett DH; Miller AB; PiƱa IL; Thomson S; Varosy PD; Zile MR; Cleland JG; Givertz MM; Metra M; Ponikowski P; Voors AA; Davison BA; Cotter G; Wolko D; Delucca P; Salerno CM; Mansoor GA; Dittrich H; O'Connor CM; Massie BM
    Drug Saf; 2012 Mar; 35(3):233-44. PubMed ID: 22339573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
    Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM
    J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
    Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure.
    Liu LCY; Valente MAE; Postmus D; O'Connor CM; Metra M; Dittrich HC; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JGF; Givertz MM; Bloomfield DM; van Veldhuisen DJ; Hillege HL; van der Meer P; Voors AA
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):281-293. PubMed ID: 28656542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study.
    Cleland JG; Chiswell K; Teerlink JR; Stevens S; Fiuzat M; Givertz MM; Davison BA; Mansoor GA; Ponikowski P; Voors AA; Cotter G; Metra M; Massie BM; O'Connor CM
    Circ Heart Fail; 2014 Jan; 7(1):76-87. PubMed ID: 24281134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
    Ter Maaten JM; Valente MA; Damman K; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Bloomfield DM; Cotter G; Davison B; Subacius H; van Veldhuisen DJ; van der Meer P; Hillege HL; Gheorghiade M; Voors AA
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27266853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function.
    Ponikowski P; Mitrovic V; O'Connor CM; Dittrich H; Cotter G; Massie BM; Givertz MM; Chen E; Murray M; Weatherley BD; Fujita KP; Metra M
    Eur J Heart Fail; 2010 Nov; 12(11):1238-46. PubMed ID: 20823097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
    Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
    Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.
    Mentz RJ; Cotter G; Cleland JG; Stevens SR; Chiswell K; Davison BA; Teerlink JR; Metra M; Voors AA; Grinfeld L; Ruda M; Mareev V; Lotan C; Bloomfield DM; Fiuzat M; Givertz MM; Ponikowski P; Massie BM; O'Connor CM
    Eur J Heart Fail; 2014 Jun; 16(6):614-24. PubMed ID: 24771609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
    Davison BA; Metra M; Cotter G; Massie BM; Cleland JGF; Dittrich HC; Edwards C; Filippatos G; Givertz MM; Greenberg B; Ponikowski P; Voors AA; O'Connor CM; Teerlink JR;
    JACC Heart Fail; 2015 May; 3(5):395-403. PubMed ID: 25951761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data.
    Metra M; Cotter G; Senger S; Edwards C; Cleland JG; Ponikowski P; Cursack GC; Milo O; Teerlink JR; Givertz MM; O'Connor CM; Dittrich HC; Bloomfield DM; Voors AA; Davison BA
    Circ Heart Fail; 2018 May; 11(5):e004644. PubMed ID: 29748350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.
    O'Connor CM; Fiuzat M; Lombardi C; Fujita K; Jia G; Davison BA; Cleland J; Bloomfield D; Dittrich HC; Delucca P; Givertz MM; Mansoor G; Ponikowski P; Teerlink JR; Voors AA; Massie BM; Cotter G; Metra M
    Circ Heart Fail; 2011 Nov; 4(6):724-32. PubMed ID: 21900185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites.
    Stroh M; Hutmacher MM; Pang J; Lutz R; Magara H; Stone J
    AAPS J; 2013 Apr; 15(2):498-504. PubMed ID: 23355301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function trajectories and clinical outcomes in acute heart failure.
    Givertz MM; Postmus D; Hillege HL; Mansoor GA; Massie BM; Davison BA; Ponikowski P; Metra M; Teerlink JR; Cleland JG; Dittrich HC; O'Connor CM; Cotter G; Voors AA
    Circ Heart Fail; 2014 Jan; 7(1):59-67. PubMed ID: 24281137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
    Stroh M; Dishy V; Radziszewski W; Hwang E; Lazarus-Shipitofsky N; Dittrich H; Johnson-Levonas AO; Lutz R; Wagner JA; Lai E
    Am J Ther; 2010; 17(1):53-60. PubMed ID: 20027108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.